Skip to main content
News > News > Announcing Proteome Antibiotics, a Joint Venture

Announcing Proteome Antibiotics, a Joint Venture

Bacmine and Open Therapeutics (Cincinnati, US) have signed license agreements to develop and commercialize technology generated by Bacmine to identify and characterize essential bacterial proteins as novel targets for antibiotics.

This discovery platform constructs large libraries of recombinant, single-domain antibodies using whole proteomes from pathogens as antigens. The outcome of the screening of these libraries through proprietary methods is a list of essential proteins, with their functionally essential epitopes characterized by the interaction with the antibody. The antibody-protein complex can be isolated and solved by physical and enzymatic methods, to reveal those protein surfaces that are essential for function, and provide information that streamlines the de novo design of antibiotics or the screening of combinatorial libraries of soluble molecules.

 

See Bacmine Release: click here.

G_7tL8ya_400x400

For more information, contact jason@microbialrobotics.com

Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.

Please read our Open Therapeutics’ company whitepaper.

Secured By miniOrange